{
  "docId": "019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "docSlug": "jarvis-elliott-management-gsk-letter-july-2021",
  "documentTitle": "Elliott Management GSK Letter July 2021",
  "authorId": "elliott-management-gsk-letter-july-2021",
  "authorName": null,
  "documentKindSlug": "document",
  "documentKindLabel": "Document",
  "sourceTypeSlug": "independent_analyst",
  "sourceTypeLabel": "Independent analyst",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 10,
  "pageCount": 19,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 15,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1354-774d-98d0-be219b0f6eb3/10",
  "deckHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3",
  "deckJsonHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3.json",
  "deckAnchorHref": "/decks/019f6b8f-1354-774d-98d0-be219b0f6eb3#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.764,
        "x": 0.118,
        "y": 0.85
      },
      "kind": "other",
      "text": "5 Based on leading management consulting firm analysis\n6 2020 organic growth of 4% and Visible Alpha consensus 2022 growth of 4%.\n7 Based on 2020 company reporting. Leading management consulting firm analysis\n8 Based on leading industry data providers. Leading management consulting firm analysis",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ef6e73e-49c8-429a-9fa2-352a2ea5eacd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.764,
        "x": 0.118,
        "y": 0.125
      },
      "kind": "paragraph",
      "text": "CH is the global leader in the consumer health market and, after separation, will be the only major listed pure-play consumer health company, with leadership positions in a number of highly attractive and growing categories:5",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fa2e835-cb2d-4dec-89a1-ae1ce795696c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.265,
        "w": 0.764,
        "x": 0.118,
        "y": 0.473
      },
      "kind": "paragraph",
      "text": "Driven by leading brands, strong R&D capabilities, solid pricing power and robust market volume growth, CH has a ~4% organic growth outlook, comparing favourably to its consumer packaged goods peers. Further, CH has significant upside margin potential, with EBITDA margins ~5% below the consumer health peer average, despite its globally leading scale and focus on high gross margin global power brands. This margin expansion could drive significant EPS growth well in excess of top line growth, providing another attractive element to the equity story. As an independent business, Consumer Health will be able to set its own agenda on investments and capital allocation, positioning the business to benefit from potential consolidation in the industry, and allowing the business to target growth in line with or exceeding the 5% industry growth rate. This means CH can grow faster, invest better, improve its efficiency and, as a result, provide better products to more customers. This dynamic makes CH a highly attractive company, both as a standalone investment and as a potential strategic target for other players in the industry.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88048f58-0fac-4853-81a0-4c8920a8fbf9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.235,
        "w": 0.764,
        "x": 0.118,
        "y": 0.185
      },
      "kind": "table",
      "text": "Segment, Key brands, '18-20 Mkt. Growth, Global Market Position. Oral health, Sensodyne/Aquafresh/Polident, 4.7%, 3rd (1st in Europe). Analgesics, Voltaren/Advil/Panadol, 4.4%, 1st. Cough, Cold and Allergy, Centrum/Caltrate, 2.9%, 1st. V&D, Flonase/Otrivine, 5.2%, 2nd (1st in Europe). Digestive health, Tums/Eno/Nexium, 3.5%, 1st. Overall, -, 3-5%, 1st.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e03c5be-1879-4ac3-8965-66f2376cb568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.335,
        "x": 0.118,
        "y": 0.092
      },
      "kind": "title",
      "text": "Appendix I: GSK Consumer Healthcare",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25e4684c-cc23-4279-b2ff-82ff51b5f3ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "bb6d245c-c310-404e-966f-079fd0e512d9",
      "evidence": "table/data: Segment, Key brands, '18-20 Mkt. Growth, Global Market Position.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "1c482301-3d23-44a1-b294-225fd6d38013",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 10-11 provide appendix data supporting the argument.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}